146 related articles for article (PubMed ID: 8708151)
1. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma.
Alpsoy E; Yilmaz E; Başaran E; Yazar S
J Dermatol; 1996 Jun; 23(6):394-6. PubMed ID: 8708151
[TBL] [Abstract][Full Text] [Related]
2. Intralesional alfa-2a interferon therapy for basal cell carcinoma.
Doğan B; Harmanyeri Y; Baloğlu H; Oztek I
Cancer Lett; 1995 May; 91(2):215-9. PubMed ID: 7767912
[TBL] [Abstract][Full Text] [Related]
3. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.
Chimenti S; Peris K; Di Cristofaro S; Fargnoli MC; Torlone G
Dermatology; 1995; 190(3):214-7. PubMed ID: 7599384
[TBL] [Abstract][Full Text] [Related]
4. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.
Fernández-Vozmediano JM; Armario-Hita JC
J Drugs Dermatol; 2010 Apr; 9(4):381-4. PubMed ID: 20514797
[TBL] [Abstract][Full Text] [Related]
5. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited.
Kim KH; Yavel RM; Gross VL; Brody N
Dermatol Surg; 2004 Jan; 30(1):116-20. PubMed ID: 14692941
[TBL] [Abstract][Full Text] [Related]
6. Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database.
Sato I; Shimbo T; Kawasaki Y; Masaki N
Drug Des Devel Ther; 2015; 9():283-90. PubMed ID: 25565777
[TBL] [Abstract][Full Text] [Related]
7. Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma.
Shiell A
Australas J Dermatol; 1994; 35(2):71-5. PubMed ID: 7702490
[TBL] [Abstract][Full Text] [Related]
8. Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial.
Maleki M; Layegh P; Kiafar B; Teimoorian M; Darchini-Maragheh E; Razmara M
Expert Rev Anticancer Ther; 2023 Jul; 23(7):753-760. PubMed ID: 37256542
[TBL] [Abstract][Full Text] [Related]
9. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression.
Buechner SA
J Am Acad Dermatol; 1991 May; 24(5 Pt 1):731-4. PubMed ID: 1869644
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
12. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
13. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.
Edwards L; Tucker SB; Perednia D; Smiles KA; Taylor EL; Tanner DJ; Peets E
Arch Dermatol; 1990 Aug; 126(8):1029-32. PubMed ID: 2383027
[TBL] [Abstract][Full Text] [Related]
14. Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up.
Krilis M; Tsang H; Coroneo M
Ophthalmology; 2012 Oct; 119(10):1969-73. PubMed ID: 22704834
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy.
Tucker SB; Polasek JW; Perri AJ; Goldsmith EA
J Am Acad Dermatol; 2006 Jun; 54(6):1033-8. PubMed ID: 16713458
[TBL] [Abstract][Full Text] [Related]
16. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon.
Mozzanica N; Cattaneo A; Boneschi V; Brambilla L; Melotti E; Finzi AF
Arch Dermatol Res; 1990; 282(5):311-7. PubMed ID: 2221983
[TBL] [Abstract][Full Text] [Related]
17. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
18. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
Boussiotis VA; Pangalis GA
Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
20. Intralesional interferon therapy for basal cell carcinoma.
Cornell RC; Greenway HT; Tucker SB; Edwards L; Ashworth S; Vance JC; Tanner DJ; Taylor EL; Smiles KA; Peets EA
J Am Acad Dermatol; 1990 Oct; 23(4 Pt 1):694-700. PubMed ID: 2229497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
